Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the development of novel immuno-cellular therapies for the treatment of cancer. The company's lead product candidate, GLS-100, is a personalized, off-the-shelf CAR T-cell therapy that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). Gracell has a pipeline of other CAR T-cell therapy candidates that are targeting a variety of cancer indications, including multiple myeloma, non-Hodgkin lymphoma, and solid tumors.
Gracell was founded in 2015 by Dr. Xin Wang, a leading expert in CAR T-cell therapy. The company is headquartered in Shanghai, China, and has offices in the United States and Europe. Gracell has raised over $500 million in funding from investors such as Sequoia Capital China, Lilly Asia Ventures, and Fortis Capital.
Gracell's CAR T-cell therapy platform is based on the company's proprietary Gracell Immune Engineering Platform (GIEP). GIEP is a gene editing platform that allows Gracell to engineer CAR T cells with high specificity and potency. The platform has been used to create a variety of CAR T-cell therapy candidates that are targeting a range of cancer indications.
GLS-100 is Gracell's lead product candidate. GLS-100 is a personalized, off-the-shelf CAR T-cell therapy that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of relapsed/refractory B-cell ALL. The trial is enrolling patients who have failed to respond to standard treatment options. GLS-100 has shown promising results in the trial, with some patients achieving complete remission.
Gracell has a pipeline of other CAR T-cell therapy candidates that are targeting a variety of cancer indications. These include:
In addition to its CAR T-cell therapy platform, Gracell is also developing other immuno-cellular therapies, such as natural killer (NK) cell therapies and tumor-infiltrating lymphocyte (TIL) therapies. These therapies are designed to harness the power of the immune system to fight cancer.
Gracell is a rapidly growing company with a bright future. The company is well-positioned to make significant advances in the treatment of cancer.
Here are some additional details about Gracell Biotechnologies Inc.:
Market capitalization: $1.3 billion (as of March 8, 2023)